Do we need new phosphate binders in dialysis?

Abstract Patients affected by chronic kidney disease (CKD) have a greater risk of mortality than the general population. Fatal cardiovascular events are the most frequent cause of death in CKD patients, especially in the late stages of disease. Derangement of mineral metabolism and hyperphosphataemi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Kidney Journal 2021-02, Vol.14 (2), p.474-475
Main Authors: Cozzolino, Mario, Galassi, Andrea, Ciceri, Paola
Format: Article
Language:English
Subjects:
Calcium carbonate
Chronic kidney failure
Epidemiology
Medical research
Medicine, Experimental
Mortality
Phosphates
Physiological aspects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Patients affected by chronic kidney disease (CKD) have a greater risk of mortality than the general population. Fatal cardiovascular events are the most frequent cause of death in CKD patients, especially in the late stages of disease. Derangement of mineral metabolism and hyperphosphataemia are currently accepted as pivotal triggers of these vascular complications. Phosphate binders represent the common strategy to counteract hyperphosphataemia in dialysis patients. Several studies have reported a reduction in mortality risk in dialysis patients receiving phosphate binders compared with untreated patients, independent of the class of binder prescribed.
ISSN:2048-8505
2048-8513
DOI:10.1093/ckj/sfaa246